drugset / Trial / NCT00709592

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

NCT00709592

RandomizedParallel-groupOpen-labelTreatment

Summary

One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.

Timeline

Start
2008-07-21
Primary completion
2014-02-15
Completion
2017-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Thymoglobulin Protein / enzyme biologic 1.7 mg/kg Intravenous
Subject Thymoglobulin Protein / enzyme biologic 2.5 mg/kg Intravenous
Background Mycophenolate Mofetil Small molecule Oral
Background Tacrolimus Small molecule Oral